Pentosan polysulfate

Drug Profile

Pentosan polysulfate

Alternative Names: AK-150; Elmiron; NaPPS

Latest Information Update: 02 Jun 2016

Price : $50

At a glance

  • Originator IVAX Corporation
  • Developer Asahi Kasei; Multiplex Pharma Holdings
  • Class Anti-inflammatories; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain
  • Phase II Spinal cord disorders
  • Phase I/II Mucopolysaccharidosis VI
  • Suspended Mucopolysaccharidosis I
  • Discontinued Osteoarthritis

Most Recent Events

  • 24 May 2016 ReqMed completes phase II clinical trials in Spinal cord disorders (HTLV-1-associated myelopathy) in Japan (SC) prior to May 2016
  • 29 Dec 2015 Phase-II clinical trials in Spinal cord disorders (HTLV-1-associated myelopathy) in Japan (SC) prior to December 2015
  • 04 Apr 2015 Suspended - Phase-II for Mucopolysaccharidosis I in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top